SOLV Solventum
Separation noise hides a steady 20%-margin healthcare franchise; modest upside if one-offs truly stop.
The story
Solventum is the 3M healthcare spin-off: wound care (MedSurg), dental, and health information systems. These are sticky, mid-single-digit-growth franchises with real brand and installed-base moats, but the company carries meaningful spin-related debt. It is a mature business still working through separation: it is untangling from 3M's IT and supply chain, has sold its filtration unit, and is deleveraging. That process puts noise in reported margins but has not changed the core economics.
I kept the drivers essentially unchanged. The 5.1% TTM margin looks like separation, restructuring and impairment charges, not lost pricing power, because revenue held flat at about $8.2B. Annual margins have still landed at 20-25% outside the charge-heavy year. I trimmed the target margin slightly, from 22.5% to 22%, because the run of one-offs is recurring more than a truly clean spin would. Beta stays at 1.1 to reflect $4.2B of net debt.
Value drivers
| Revenue growth (Y1) | 2.0% |
| Terminal growth | 2.5% |
| Forecast horizon | 6y |
| Target operating margin | 22.0% |
| Years to target margin | 4 |
| Sales-to-capital | 0.85 |
| Beta | 1.10 |
| Failure probability | 2.5% |
| Cost of capital (WACC) | 10.0% |
| Terminal WACC | 9.6% |
Valuation bridge
| PV of explicit FCFF | 4.98B |
| PV of terminal value | 11.23B |
| Equity value | 11.76B |
| ÷ shares → per share | $69.19 |
Projected free cash flow to the firm
| Yr | Revenue | Growth | Margin | NOPAT | Reinvest | FCFF | PV |
|---|---|---|---|---|---|---|---|
| 1 | 8.33B | 2.0% | 9.3% | 704.99M | 192.05M | 512.95M | 466.49M |
| 2 | 8.50B | 2.1% | 13.5% | 1.05B | 205.68M | 840.39M | 695.06M |
| 3 | 8.69B | 2.2% | 17.8% | 1.40B | 220.00M | 1.18B | 889.47M |
| 4 | 8.89B | 2.3% | 22.0% | 1.78B | 235.06M | 1.54B | 1.05B |
| 5 | 9.10B | 2.4% | 22.0% | 1.82B | 250.92M | 1.57B | 975.21M |
| 6 | 9.33B | 2.5% | 22.0% | 1.86B | 267.65M | 1.60B | 903.14M |
Key risks
- 'One-time' separation and restructuring costs keep recurring and permanently cap margins below 20%
- Wound care faces pricing pressure and competition, and dental demand is cyclical
- Leverage limits flexibility if exiting 3M's transition-services agreements costs more than planned
Catalysts
- Clean quarters after the 3M transition-services agreements end show 20%+ operating margins
- Proceeds from the filtration sale pay down debt, cutting interest costs and equity risk